ARTERIAL OXYGEN-SATURATION - EFFECTS OF ALTITUDE AND PENTOXIFYLLINE

被引：4
作者：
WOOD, SC
APPENZELLER, O
GREENE, ER
ELDRIDGE, M
机构：
[1] Lovelace Medical Foundation, Albuquerque, New Mexico
[2] Department of Pediatrics, University of Utah, Salt Lake City, Utah
来源：
JOURNAL OF WILDERNESS MEDICINE | 1992年 / 3卷 / 03期
基金：
美国国家卫生研究院;
关键词：
PENTOXIFYLLINE; ALTITUDE; ARTERIAL SATURATION; VISCOSITY;
D O I：
10.1580/0953-9859-3.3.250
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Maximum heart rate declines at high altitude, presumably due to hypoxic depression of the heart. Pentoxifylline, a rheologically active drug, increases maximum heart rate at high altitude. We tested the hypothesis that pentoxifylline increases oxygen saturation of arterial blood, which for coronary arterial blood could explain the chronotropic effect. The study was conducted in Sikkim. Twelve subjects were tested at 2100 m, 2730 m, and 4600 m altitude. In a double blind protocol, 6 subjects took pentoxifylline (1200 mg per day) each day for five weeks before and during the study. Control subjects (n = 6) took a placebo. The most important finding was a significantly higher resting arterial saturation at 4600 m in the subjects taking pentoxifylline (80.7% versus 75.4% in the control group). Possible mechanisms of this action of pentoxifylline include improved pulmonary gas exchange.
引用
收藏
页码：250 / 255
页数：6
相关论文
共 12 条
  • [1] Angelkort B., Marvin N., Boateng K., Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease, Curr Med Res Opin, 6, pp. 255-258, (1979)
  • [2] Matzky R., Darius H., Schror K., The release of prostacyclin (PDI<sub>2</sub>) by pentoxifylline from human vascular tissue, Arzneimittel Forsch, 32, pp. 1315-1319, (1982)
  • [3] Hakim T.S., Reversal of pulmonary hypoxic vasoconstriction with pentoxifylline and aminophylline in isolated lungs, Can J Physiol Pharmacol, 66, pp. 146-151, (1987)
  • [4] Appenzeller O., Wood S.C., Pentoxifylline: thermoregulatory and vasomotor effects at altitude, Ann Sports Med, 4, pp. 279-285, (1988)
  • [5] Wood S.C., Appenzeller O., Effects of pentoxifylline on blood rheological properties and exercise performance of endurance-trained athletes at high altitude, Ann Sports Med, 4, pp. 263-269, (1988)
  • [6] Pugh L.G.C.E., Cardiac output in muscular exercise at 5,800 m (19,000 ft), J Appl Physiol, 19, pp. 441-447, (1964)
  • [7] Hedemark L.L., Kronenberg R.S., Ventilatory and heart rate response to hypoxia and hypercapnia during sleep in adults, J Appl Physiol, 53, pp. 307-312, (1982)
  • [8] Chick T.W., Scotto P., Icenogle M.V., Sikes C.W., Doyle M.P., Wood S.C., Loeppky J., Effects of pentoxifylline on pulmonary hemodynamics during hypoxia in anesthetized dogs, Am Rev Resp Dis, 137, pp. 1099-1103, (1988)
  • [9] Sturani C., Palareti G., Poggi M., Schiavian M., Torricelli P., Papiris S., Coccheri S., Gunella G., Pulmonary vascular reactivity and hemorheology in patients with chronic cor pulmonale: responses to pentoxifylline at rest and during exercise, La Ricercal Clin Lab, 16, pp. 569-578, (1986)
  • [10] Chatterji J.C., Ohri V.C., Das B.K., Chadha K.S., Akhtar M., Platelet count, platelet aggregation, and fibrinogen levels following acute induction to high altitude, Thrombosis Res, 26, pp. 177-182, (1982)
12